Physician profile
Taylor Johnson
NPI 1144825548
$6,282.30
in general payments reported to CMS, 2019-2025
39 companies · $587 in 2025
The $587 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $791 · 2022: $1,400 · 2023: $1,661 · 2024: $1,844 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,917 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.28 |
| Education | $174.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $654.52 | 2021-2024 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $635.15 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.67 | 2021-2024 | Jardiance |
| Amgen INC. | $459.43 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $445.66 | 2022-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $423.71 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $395.04 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $303.86 | 2022-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $242.44 | 2022-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $225.70 | 2024 | |
| Amarin Pharma, INC. | $165.41 | 2021-2023 | |
| Abiomed | $136.34 | 2025 | |
| Sanofi-Aventis U.S. LLC | $132.16 | 2022-2024 | |
| Mylan Specialty L.P. | $131.30 | 2022-2024 | Yupelri |
| Pfizer INC. | $130.76 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.